## THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

# 2022 CARDIO ONCOLOGY SYMPOSIUM FRIDAY, MARCH 18, 2022

### Agenda

Moderators: Daniel Addison, MD and Bhuvaneswari Ramaswamy, MD, MRCP

Module 1	
7:50am	Welcome and housekeeping remarks
	Ayesha Hasan, MD and Raphael Pollock, MD, PhD
8:00	Managing Acute Coronary Syndromes in Cancer Patients
	Richard Gumina, MD, PhD
8:15	Device Therapy in Cancer Patients
	Mohammad Afzal, MBBS
8:30	Managing Advanced Heart Failure in Cancer Patients
	Richard Cheng, MD
8:45	Ibrutinib-induced Cardiac Arrhythmias
	Seema Bhat, MD
9:00	Emerging and Potential Roles of Genetics within Cardio-Oncology
	Ray Hershberger. MD
9:15	Optimal uses of STRAIN Imaging in Patients with Cancer
	Michael Wesley Milks, MD
9:30	Big Data to Inform Modern Cardio-Oncology
	Avirup Guha, MD, RPVI
9:45	Identifying and Managing Radiation Induced CVD
	Eric Miller, MD, PhD
10:00	BREAK
	BREAK
Module 2	
	Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Module 2 10:10am	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS
Module 2	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity
Module 2 10:10am 10:25	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH
Module 2 10:10am	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient
Module 2 10:10am 10:25 10:40	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient Scott Lilly, MD, PhD
Module 2 10:10am 10:25	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic
Module 2 10:10am 10:25 10:40 10:55	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic Tochukwu M. Okwuosa, DO
Module 2 10:10am 10:25 10:40	Cardiovascular Toxicities of Immune Checkpoint Inhibitors Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient
Module 2 10:10am 10:25 10:40 10:55	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD
Module 2 10:10am 10:25 10:40 10:55 11:10	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD Role CH/CHIP in Cardiovascular Disease
Module 2 10:10am 10:25 10:40 10:55 11:10	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD
Module 2 10:10am 10:25 10:40 10:55 11:10 11:25	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD Role CH/CHIP in Cardiovascular Disease     Uma Borate, MBBD
Module 2 10:10am 10:25 10:40 10:55 11:10 11:25	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD Role CH/CHIP in Cardiovascular Disease     Uma Borate, MBBD Managing Hypertension after Cancer Therapy Initiation
Module 2 10:10am  10:25 10:40 10:55 11:10 11:25 11:40	Cardiovascular Toxicities of Immune Checkpoint Inhibitors     Ajay Vallakati, MBBS Emerging Directions in Tyrosine Kinase Inhibitor Cardiac Toxicity     Sakima Smith, MD, MPH Managing Valvular Heart Disease in the Cancer Patient     Scott Lilly, MD, PhD Impending Optimal Preventive Strategies in the Cardio-Oncology Clinic     Tochukwu M. Okwuosa, DO Use of Advanced Cardiac Imaging in the Cancer Patient     Daniel Addison, MD Role CH/CHIP in Cardiovascular Disease     Uma Borate, MBBD Managing Hypertension after Cancer Therapy Initiation     Jason Prosek, MD

#### Cardiotoxicity after Cellular (CAR-T Cell) Therapies 12:10 Jonathan Brammer, MD

Modul	e 3
-------	-----

Module 3		
Breakout Sessions:		
12:55pm	Welcome and housekeeping	
	Dr. Addison	
Breakout A	Cancer Immune Checkpoint Inhibitor Associated Cardiotoxicities	
	Margaret Gatti-Mays, MD; Timothy Gauntner, DO, PhD; Avirup Guha, MD, RPVI;	
	Tochukwu M. Okwuosa, DO; and Ajay Vallakati, MBBS	
1:00	Case Scenario (immune Checkpoint Myocarditis)	
	Timothy Gauntner, DO, PhD	
1:05	Case Scenario (CAR-T cell induced arrhythmias and heart failure)	
	Timothy Gauntner, DO, PhD	
1:10	Panel Discussion of Cases	
	Margaret Gatti-Mays, MD; Timothy Gauntner, DO, PhD; Avirup Guha, MD, RPVI;	
	Tochukwu M. Okwuosa, DO; and Ajay Vallakati, MBBS	
1:30	Keynote Lecture: Immunotherapy-associated Cardiotoxicity -Where are We Going	
	Javid Moslehi, MD	
Breakout B	Novel Cancer Targeted and Immune Therapy associated Cardiotoxicities	
	Daniel Addison, MD; Jonathan Brammer, MD; Zachary Braunstein, MD;	
	Richard Cheng, MD; and Mahmoud Houmsse, MD	
1:55	Case Scenarios (Ibrutinib associated Atrial Fibrillation)	
	Zachary Braunstein, MD	
2:00	Case Scenarios (Stem cell transplant associated CHF)	
	Zachary Braunstein, MD	
2:05	Panel Discussion:	
	Daniel Addison, MD; Jonathan Brammer, MD; Zachary Braunstein, MD;	
	Richard Cheng, MD; and Mahmoud Houmsse, MD	
2:25	Cardiac Medication Management Among Patients Receiving BTK Inhibitors	
	Jordan Lundberg, PharmD	
2:50pm – 3:05pm Break		
2.55p 5.65p Break		

Breakout C	Cardiac Amyloidosis in the 21 <sup>st</sup> Century
	Naresh Bumma, MD; Courtney Campbell, MD, PhD; and Katarzyna Mikrut, MD;
3:05	Case Scenarios (Indeterminate PYP Imaging, and course of care)
	Katarzyna Mikrut, MD
3:10	Case Scenarios (CHF in Myeloma, and Orthopedic associations)
	Katarzyna Mikrut, MD
3:15	Panel Discussion:
	Naresh Bumma, MD; Courtney Campbell, MD, PhD; and Katarzyna Mikrut, MD, and
	Ajay Vallakati, MBBS
3:35	Keynote: Modern Directions in Cardiac Amyloidosis
	Sharmila Dorbala, MD
3:35	•